Share on StockTwits

Investment analysts at Stifel Nicolaus began coverage on shares of Loxo Oncology (NASDAQ:LOXO) in a note issued to investors on Tuesday, reports. The firm set a “buy” rating and a $20.00 price target on the stock. Stifel Nicolaus’ price objective suggests a potential upside of 53.73% from the stock’s previous close.

Loxo Oncology (NASDAQ:LOXO) traded up 1.31% on Tuesday, hitting $13.18. 44,889 shares of the company’s stock traded hands. Loxo Oncology has a one year low of $12.687 and a one year high of $13.42. The stock has a 50-day moving average of $13.03 and a 200-day moving average of $13.03. The company’s market cap is $210.1 million.

Separately, analysts at JMP Securities initiated coverage on shares of Loxo Oncology in a research note on Tuesday, August 26th. They set an “outperform” rating and a $23.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and an average target price of $20.75.

Loxo Oncology, Inc (NASDAQ:LOXO) develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations.

The Fly On The Wall

Receive News & Ratings for Loxo Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.